ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
9.43
+0.10 (1.07%)
May 2, 2024, 3:40 PM EDT - Market open

ARS Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018
Market Capitalization
9105263082341,321--
Market Cap Growth
-71.03%31.66%-82.32%---
Enterprise Value
651298341839395-13
PE Ratio
-9.68-9.68-8.87-11.54-40.11--
PS Ratio
29304.3217535.50233.7242.43---
PB Ratio
3.812.281.13-7.473.45--
P/FCF Ratio
-8.85-8.85-7.64-13.26-41.15--
P/OCF Ratio
-8.88-8.88-7.67-13.30-42.36--
EV/Sales Ratio
21701.459932.6325.5933.16---
EV/EBITDA Ratio
-5.49-5.49-0.97-9.12-30.08-0.230.82
EV/EBIT Ratio
-5.48-5.48-0.97-9.02-28.51-0.210.75
EV/FCF Ratio
-5.01-5.01-0.84-10.36-29.23-0.270.76
Debt / Equity Ratio
0.000.000.00-0.290.01-0.27-0.22
Debt / EBITDA Ratio
-0.01-0.01-0.01-0.45-0.13-0.69-0.48
Debt / FCF Ratio
0.000.00-0.01-0.51-0.13-0.82-0.45
Quick Ratio
95.5195.5150.407.3440.300.594.06
Current Ratio
96.9296.9251.017.4240.690.594.04
Asset Turnover
000.010.0200-
Interest Coverage
-----1135.10--
Return on Equity (ROE)
-22.20%-22.20%-12.50%-7.90%-20.30%51.10%-
Return on Assets (ROA)
-21.50%-21.50%-12.00%-7.00%-16.10%-111.00%-
Return on Capital (ROIC)
-29.23%-29.23%-12.99%87.49%-8.51%55.77%67.25%
Earnings Yield
-6.18%-10.33%-11.28%-8.67%-2.49%--
FCF Yield
-6.76%-11.30%-13.09%-7.54%-2.43%--
Buyback Yield / Dilution
-138.30%-138.30%-38.39%-893.01%-339.94%-9.45%-
Total Shareholder Return
-138.30%-138.30%-38.39%-893.01%-339.94%-9.45%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).